Briefing

Last week, the German Pain and Palliative Care Days 2025 took place in Frankfurt. Among the numerous lectures and workshops, the use of cannabinoids was a recurring theme throughout the event. Approximately 14 million people in Germany suffer from chronic pain – a serious public health issue that severely affects daily life and is often associated with psychological burdens. It is all the more important that the use of cannabinoids in pain medicine continues to gain significance. 

Cannabinoids in Pain Therapy 

Cannabinoids work through the body’s endocannabinoid system by reducing inflammation, dampening nerve irritations, and influencing pain processing in the brain. In palliative care, they also alleviate nausea and improve sleep. 

Cannabinoids exert their effects through two main receptors. CB1 receptors, primarily found in the central nervous system, inhibit neurotransmitter release and reduce the perception of pain. CB2 receptors, primarily located in immune cells, contribute to anti-inflammatory effects by decreasing the release of pro-inflammatory cytokines. 

Cannabinoids as an Alternative or Complement to Opioids 

Studies have shown that cannabinoids can be used both as a complement to and an alternative to opioids. A 2017 patient survey with 2,897 participants reveals impressive results. 78% of respondents reported better pain reduction compared to pure opioid therapy, 88% found the side effect profile more favorable, and 97% were able to reduce their opioid dosage. These numbers highlight the potential of cannabinoids, particularly in minimizing opioid-associated risks like addiction and side effects. 

Regulatory Challenges and Future Outlook 

The motto of the congress was “Individualization instead of Standardization” – a reflection of how urgently we need to bridge the gap between scientific knowledge and the specific needs in pain therapy. Practical reports show that, despite growing acceptance of cannabinoid-based medications, doctors are often faced with strict regulations and complex procedures before they can issue prescriptions covered by statutory health insurance (GKV). 

Therefore, it is crucial to simplify the prescription processes and integrate cannabinoids more strongly into the established pain therapy guidelines. Only through targeted research and reducing regulatory barriers can we ensure that patients receive the best possible support they need. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

What is the Endocannabinoid System?

The Endocannabinoid System (ECS) is a complex network of natural compounds, receptors, and enzymes present in the human body. It influences various physiological processes, including pain regulation, brain development, appetite, reproduction, and gut motility.[1] This system is found in nearly all living organisms—except insects—highlighting its essential importance for vital body functions. The ECS is named after the discovery that certain compounds from the cannabis plant, known as phytocannabinoids, can have effects similar to those of endogenous cannabinoids produced by the body. The primary psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), binds to the same receptors as these natural substances.

Although the ECS was discovered in the 1960s, many of its functions remain incompletely understood. Its gender-specific effects, in particular, have not been adequately explored.

Why is the ECS Relevant for Women’s Health?

It is well established that the ECS is closely linked to hormonal processes. Studies show that it plays a role in regulating the menstrual cycle, fertility, and menopause.[2][3] The potential for treating female-specific conditions such as endometriosis, premenstrual syndrome (PMS), or chronic pain is particularly intriguing. The ECS could be a key to new therapeutic approaches; however, there are currently few targeted clinical studies examining medical cannabis for these indications.

A better understanding of the ECS is not only scientifically desirable but also urgently needed. Women are often overlooked in medical research, and many of their ailments remain underdiagnosed or inadequately treated. Medical cannabis could offer an alternative or complementary option, especially for patients who do not respond sufficiently to conventional therapies. Furthermore, women tend to experience chronic pain more frequently, which is one of the most common applications of medical cannabis. Therefore, it is even more important to investigate pain perception and the response to pain medication from a gender-specific perspective.[4]

Why We Need More Gender-Specific Research

On the occasion of this year’s International Women’s Day, it is time to bring this topic into sharper focus. A better understanding of the ECS could not only help to apply medical cannabis more effectively but also open new doors for personalized medicine. A gender-specific approach in cannabis research is long overdue.

[1] Fowler, C. J. (2010). Anandamide uptake explained? Trends in Pharmacological Sciences, 33(4), 181–185.
[2] Santoro, A., Mele, E., Marino, M., Viggiano, A., Nori, S. L., & Meccariello, R. (2021). The complex interplay between the endocannabinoid system and the estrogen system in the central nervous system and periphery. International Journal of Molecular Sciences, 22(2), 972. https://doi.org/10.3390/ijms22020972
[3] Di Blasio, A. M., Vignali, M., & Gentilini, D. (2013). The endocannabinoid pathway and the female reproductive organs. Journal of Molecular Endocrinology, 50(1), R1-9. https://doi.org/10.1530/JME-12-0182
[4] Schmerzgesellschaft. (n.d.). Schmerz bei Frauen und Männern. Abgerufen von https://www.schmerzgesellschaft.de/patienteninformationen/besonderheiten-bei-schmerz/schmerz-bei-frauen-und-maenner

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

International Industry Meetings: Exchange at the Highest Level

Germany remains a key player in the European cannabis industry. The ICBC Berlin (April 29-30, 2025) is the leading international event for the German market, bringing together businesses, investors, and policymakers. Market developments are discussed here, partnerships are forged, and the next steps for the industry are shaped.

Focusing on the medical sector, the Medical Cannabis Congress (June 12-13, 2025) in Berlin provides a dedicated platform for physicians, scientists, and pharmacists to discuss the latest advancements in cannabis therapy.
Similarly, the German Pain and Palliative Care Congress (March 12-16, 2025) in Frankfurt will explore the role of medical cannabis—especially in pain management, which has gained new momentum following regulatory changes last year.
The discussion on Europe’s cannabis market extends beyond national borders. In London, Cannabis Europa (June 24-25, 2025) will focus on regulatory developments, economic opportunities, and industry challenges across the continent. This event is particularly relevant for companies and investors looking to expand internationally.

Germany as a Hub for Cannabis Events

Germany continues to establish itself as a central hub for cannabis events. Mary Jane Berlin (June 19-22, 2025) remains one of Germany’s largest hemp fairs and is unique in covering all aspects of the industry: adult-use cannabis, CBD, industrial hemp, and medical cannabis. The event attracts tens of thousands of visitors annually—including consumers, activists, and businesses—making it a key meeting point for the entire industry.

For professionals in the pharmaceutical industry and the pharmacy sector, Expopharm in Düsseldorf (September 18-20, 2025) is an essential event. With a growing focus on medical cannabis, the role of pharmacies in patient care is becoming increasingly significant. This trade show serves as a key platform for stakeholders involved in the distribution, prescription, and application of medical cannabis.

Looking Beyond Borders: Global Highlights

For those looking to connect with the international cannabis industry, MJBizCon in Las Vegas (December 2-5, 2025) is an unmissable event. As the world’s largest cannabis trade show, it attracts tens of thousands of attendees from all sectors of the industry—from producers and brand developers to investors and policymakers.

The Future of Cannabis: What Lies Ahead in 2025

The cannabis industry remains in motion, and 2025 promises to be a year of exciting developments. The range of upcoming events highlights the industry’s dynamism and innovative potential—both in Germany and globally.

Whether it’s regulatory milestones, medical breakthroughs, or new business models, the coming months will be pivotal. We look forward to following these developments with you and engaging in discussions at one of these key events.

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

Telemedicine: An Opportunity or a Challenge?

While medical cannabis is becoming increasingly destigmatized, some telemedicine services have recently come under scrutiny. In particular, concerns have been raised about the practice of issuing prescriptions based solely on an online questionnaire without direct doctor-patient interaction, raising fears of misuse. However, it is important to recognize that telemedicine has become an integral part of healthcare in many areas, offering enormous benefits to countless patients.

Telemedicine allows for quick and convenient medical consultations — especially in rural regions where specialist shortages are a pressing issue. For chronically ill patients who rely on continuous treatment, digital access to healthcare can be a major relief.

At the same time, concerns about compliance with existing regulations and quality assurance are valid. However, rather than questioning telemedicine as a whole, the discussion should focus on how to ensure proper enforcement of existing rules to safeguard both patient protection and the integrity of medical care.

A Balanced Perspective on the Debate

This debate highlights that a targeted regulatory response should not be limited to medical cannabis alone but should consider telemedicine as a healthcare model in general. There are already established legal frameworks, such as the EU Patient Mobility Directive and the Medicinal Products Advertising Act (Heilmittelwerbegesetz – HWG), which set standards for safe and regulated cross-border access to telemedical services.

The concerns surrounding telemedicine demonstrate that new digital healthcare models are not inherently problematic but require clear guidelines to ensure safe and high-quality applications. Medical cannabis is not the only field where telemedical services are playing an increasingly important role—this issue affects the entire healthcare sector.

Regulate Telemedicine Sensibly, Not Demonize It

The political debate should focus on how telemedicine can be responsibly utilized rather than portraying it as a problem in itself.

A rational, solution-oriented discussion is needed—one that involves patients, doctors, and policymakers alike.

Modern, digital healthcare solutions offer substantial benefits—not just for medical cannabis but for numerous other prescription medications.

The key challenge is to strengthen and enforce existing regulations while further developing policies that ensure quality and safety for all patients.

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

With the first issue of the new year, we spotlight a forward-looking topic: research projects on recreational cannabis. While such studies have been underway in Switzerland for about a year (see the Cansativa Experts’ Dialogue), Germany opened the door for research applications on December 11. Despite positive experiences in Switzerland, this endeavor remains new territory in Germany, leaving many questions unanswered.   

The Role of Research in the Cannabis Act 

The Cannabis Act (CanG), effective since April 2024, provides the legal framework for scientific investigations into recreational cannabis use. The goal is to gather data-driven insights to better understand its impact on consumers, markets, and society. This represents a rather conservative approach designed to ensure evidence-based policymaking before implementing extensive regulatory changes.   

Diversity as the Key to Insight 

No single model can fully capture the complexities of cannabis consumption and markets. This is why research projects focus on diverse approaches and distribution models. Different regions and cities will test measures aimed at protecting youth, safeguarding health, and reducing the illegal market. This diversity is crucial to gaining insights into societal, health, and economic impacts. Particularly, analyzing market potentials and demand structures can shed light on how regulated distribution channels affect the illicit market.   

A Starting Point for Research 

The release of the new Cannabis Research Regulation in mid-December marks the beginning of a new phase (more details in the BMEL press release). Municipalities, scientific institutions, and other stakeholders can now submit their proposals. The responsible authority will determine which projects move forward. Cities such as Hanover, two Berlin districts, and Frankfurt have already expressed interest, highlighting the strong demand for robust data. Cansativa, too, is planning a model project in the Groß-Gerau district, focusing on pharmacy-based distribution (see the press release for more details).   

More Than an Experiment – A Foundation for Future Decisions 

Cannabis research projects are far more than mere experiments. They provide a foundation for regulation that considers both health and societal aspects. By testing and analyzing diverse approaches, reliable data emerges to inform responsible policymaking.   

It is now up to all stakeholders—society, researchers, and policymakers—to seize this opportunity. Together, we can lay the groundwork for informed and forward-looking cannabis regulation.   

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

The year 2024 has been a milestone for the cannabis industry in Germany. The removal of medical cannabis from the Narcotics Act and the launch of Pillar I have enabled significant progress. More recently, the release of the decree on cannabis research has opened new perspectives and provided greater planning certainty for scientific endeavors. However, the political landscape ahead of the federal election in February 2025 is causing nervousness within the industry. In this briefing, we look back at the past year and take a glimpse into the future: How will the election shape the future of cannabis regulation? 

What’s at Stake? 

The federal election is a pivotal moment for the industry. The Union party has repeatedly announced plans to roll back the Cannabis Act that has been in effect since April, often without drawing a clear distinction between recreational and medical cannabis. Such a rollback could not only halt legal recreational use but also jeopardize advancements in the medical cannabis sector – such as the simplifications in prescriptions for doctors and patients. 

At the same time, the Union has historically emphasized the need for secure access to medical cannabis. It remains critical to ensure and expand the achievements that have been steadily made since the legalization of medical cannabis in 2017. 

Scenarios for 2025: Progress or Regression? 

A conservative-led government could undo previous progress. This would not only destabilize the industry but also present new challenges for patients and consumers. A clear commitment to stable and reliable regulatory conditions would provide the industry with the planning security it needs. This could lead to increased investment, secure jobs, and Germany’s continued growth as an innovation hub for medical cannabis. 

A Look Abroad 

International developments demonstrate that the acceptance of cannabis as medicine continues to grow, with regulatory frameworks being adjusted in many countries. Denmark, for example, has been running a successful pilot program for medical cannabis since 2018. Initially planned as a temporary project, the Danish government recently decided to make the program permanent. The Czech Republic is also taking a significant step forward: From 2025, general practitioners will be allowed to prescribe medical cannabis for the first time. This decision is part of a broader plan aimed at improving access to medical cannabis and enhancing patient care. This approach could pave the way for broader societal acceptance and expand therapeutic opportunities. 

Germany has the potential to benefit from these international developments. The growing demand for medical cannabis, combined with Germany’s strong position as an exporting nation, offers enormous opportunities. However, long-term and reliable regulatory conditions are essential to strengthen the industry and remain competitive on a global scale. 

A Shared Goal 

The past years have shown how important collaboration and exchange between patients, doctors, pharmacies, and businesses are. Only through united efforts can we ensure that the industry is not set back to pre-April 2024 levels. The federal election will set the course for the future. 

As the year comes to an end, we want to extend our heartfelt thanks to all readers of the Cannabis Briefing. 2024 was a year full of challenges and opportunities, during which we made important strides together as an industry. The upcoming elections will define 2025 – and we all have a role to play in ensuring that the progress of recent years is not lost. It’s up to us to continue advancing the cannabis industry with innovative ideas, strong community spirit, and tireless dedication. 

With this in mind, we wish you and your loved ones a joyful holiday season, a happy New Year, and many bright moments ahead. Let’s approach 2025 with confidence and determination! 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

Since the legalization of medical cannabis in Germany in 2017, the industry has seen rapid growth. Yet, while some describe the current phase as a “Green Rush,” reminiscent of developments in the United States, others wonder whether the market is already moving toward consolidation. This debate is becoming increasingly relevant against the backdrop of political uncertainties and regulatory changes.

Understanding the “Green Rush”

The term “Green Rush” originated in the United States in 2012 when Washington and Colorado became the first states to legalize cannabis. This economic surge attracted entrepreneurs and investors eager to seize new market opportunities, drawing comparisons to the historical Gold Rush. Similarly, in Germany, the cannabis industry experienced significant momentum, especially following the removal of medical cannabis from the Narcotics Act (BtMG) in April 2024. This reform not only simplified the prescribing process and reduced bureaucratic barriers but also fueled industry growth.

From Disillusionment to Renewed Momentum

When Germany’s coalition government announced plans for comprehensive cannabis legalization in its 2021 coalition agreement, it sparked enthusiasm and optimism across the industry. Many businesses began preparing for a rapidly expanding market that would encompass both medical and recreational cannabis.

However, by late 2022, it became increasingly evident that the proposed legalization would not materialize as initially envisioned. Industry expectations were tempered, leading to a sense of disillusionment. Some observers even predicted an impending consolidation.

These concerns were alleviated with the removal of medical cannabis from the Narcotics Act in April 2024, which opened up new growth opportunities. Yet, challenges remain: the implementation of commercial supply chains (Pillar II) is urgently needed to adequately support the now-legal recreational market while maintaining clear separation from medical use.

Regulatory Uncertainty and Political Challenges

Today, the German cannabis market remains dynamic and continues to grow. Insights shared at the Executive Summit in Berlin two weeks ago highlighted key challenges and opportunities. For instance, only 20% of the population currently knows that medical cannabis is available as a treatment option. Raising awareness and destigmatizing cannabis remains essential to unlock the market’s untapped potential. At this stage, collaboration between industry players is more important than competition. Joint efforts are needed to educate the public and foster market development.

The consensus among experts is clear: it is too early for consolidation. The market remains vibrant, with room for innovation, growth, and new entrants. However, the looming federal election has created uncertainty about the future of cannabis regulation. The past has demonstrated that stable regulatory frameworks are critical for sustained market growth. Germany’s medical cannabis sector is still young and requires long-term perspectives to provide much-needed planning security. The upcoming government transition raises the question of whether recent progress will be preserved or if the market risks being rolled back to its state before April 1, 2024—a scenario that would create significant challenges for both the industry and patients.

A look abroad reveals a noticeable global shift in attitudes toward cannabis. In many countries, cannabis is increasingly being recognized as a legitimate medical treatment, leading to a globally rising demand. Germany has the potential to remain a leader in Europe. The coming months will be crucial in shaping the path toward a stable and innovative future for the German cannabis industry.

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

On Thursday, November 14, 2024, we hosted our exclusive event “Yes, we can Cannabizz” in Berlin—a gathering that brought together top leaders from the cannabis industry, medical professionals, patients, and pharmacists. With nearly 100 guests, the event provided a unique platform to explore the opportunities and challenges facing both the German and international cannabis markets.

For those who couldn’t attend, here’s a recap of the day’s highlights. Against the backdrop of political uncertainty and an impending government transition, the event underscored one clear message: collaboration across all stakeholders is essential to safeguard the progress made over the past months and actively shape the future of medicinal cannabis in Germany.

Event Highlights

Yes, we can Cannabizz: Berner, CEO of Cookies, and Transatlantic Perspectives

The event kicked off with a compelling business panel featuring Berner, founder and CEO of Cookies, alongside Jakob and Benedikt Sons from Cansativa Group. Moderated by Bijan Hezarkhani, the discussion offered attendees an exclusive look into the experiences of a global cannabis market leader. Since its founding in 2010, Cookies has operated across diverse international markets, navigating varying regulatory landscapes in both the medicinal and recreational sectors.

Berner emphasized the importance of quality, innovative genetics, and a patient- and consumer-focused approach as cornerstones of long-term success. His insights resonated deeply with Germany’s young and evolving cannabis industry, offering a roadmap for sustainable growth and stability. As the world’s most successful cannabis brand, Cookies set a benchmark for innovation and excellence.

Having Berner in Berlin to share his journey was a rare privilege and an inspiration for all in attendance. We thank him for joining us and providing invaluable insights that will guide the industry forward.

Yes, we can help: 200 Days of the New Cannabis Law – What’s Changed?

The second panel explored the medical landscape under the new legislation. Moderated by Bertan Türemis (Fette Pharma), the discussion brought together leading experts, including Prof. Dr. med. Kirsten R. Müller-Vahl (Medizinische Hochschule Hannover), Melanie Dolfen (Bezirksapotheke), Gero Kohlhaas (Selbsthilfenetzwerk Cannabismedizin), and Finn Age Hänsel (Sanity Group).

Since the introduction of the Medicinal Cannabis Law (MedCanG) in April 2024, several critical improvements have been made. Removing medicinal cannabis from the Controlled Substances Act has simplified prescribing processes, strengthened doctors’ autonomy, and significantly reduced administrative burdens. However, the panelists agreed that there’s still much work to be done.

The absence of Pillar II, which would establish commercial supply chains, continues to hinder the clear separation between medical and recreational cannabis use. Prof. Müller-Vahl highlighted this gap:

“Without Pillar II, the supply gap persists. Commercial structures are essential to combat the black market effectively and protect both patients and consumers.”

Adding to the industry’s concerns is the political uncertainty surrounding the upcoming government transition. The Union’s pledge to roll back parts of the cannabis legalization framework has caused widespread unease. Finn Age Hänsel voiced his worries:

“A coalition with the Union would be the worst outcome for us. They’ve already signaled their intent to stop legalization, and the SPD likely won’t push back enough.”

Yes, we can all benefit: Exploring Cannabis Quality Under the Microscope

The day concluded with an engaging workshop led by Yordanka Caglar from Tiergarten Apotheke Konstanz. Attendees had the opportunity to analyze various cultivars of medicinal cannabis under the microscope, examining quality indicators such as color, aroma, and terpene profiles. The workshop reinforced the importance of rigorous quality assurance in maintaining trust and meeting patient needs. High standards are essential for building confidence in medicinal cannabis as a therapeutic option.

The “Yes, we can Cannabizz” event demonstrated the power of collaboration and dialogue within this dynamic and growing industry. We thank all speakers and attendees for making this day a memorable one. Together, we are poised to navigate the challenges ahead and continue building a stronger, more resilient cannabis sector.

Explore more moments from ‘Yes, We Can Cannabizz’ in our picture gallery. View Gallery

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

With legalising greetings,

Clinical Studies for Improved Therapy

Clinical studies are crucial to understanding the effects of medical cannabis on conditions like chronic pain, epilepsy, and multiple sclerosis. These studies establish a scientific basis that can inform medical decisions and guide therapeutic approaches. A recent study on multiple sclerosis indicates improved quality of life with cannabis therapy, especially in physical and mental health. In palliative care, daily THC doses of 5 mg have shown potential to extend the quality and duration of life in seriously ill cancer patients.

Research also shows promising results in treating endometriosis symptoms. A European study with over 900 participants found that cannabis eased sleep disturbances, pelvic pain, and menstrual cramps. Notably, nearly 90% of patients could reduce traditional pain medication with cannabis, highlighting its potential as an alternative therapy. These clinical studies improve treatment options and help reduce biases within the medical field, promoting cannabis as a credible option in healthcare.

Preclinical Research for New Applications

Parallel to clinical studies, preclinical research is vital for exploring the biological mechanisms and potential new applications of cannabis. Compounds like CBD and THC are studied in laboratory settings to understand their interactions with the human body. This research lays the groundwork for expanding therapeutic uses and refining safety profiles. For example, a study by the University of Bonn showed in mice that low-dose THC administration might slow brain aging processes. An Australian study examined the effects of specific cannabinoids on inflammation and neuroprotective properties, particularly related to neurodegenerative diseases like Alzheimer’s. The findings suggest that cannabinoids can reduce inflammatory markers and prevent nerve cell damage in preclinical models. Such findings provide the foundation for new therapeutic approaches, though clinical trials in humans are needed to confirm these effects.

Studies on Destigmatization and Education As discussed in previous briefings, Switzerland has already launched several scientifically supervised pilot projects examining the impact of regulated cannabis sales on consumption behavior. These findings help differentiate the cannabis discourse and reduce societal prejudices. In Germany, the legal foundation for cannabis regulation has been established with the new Cannabis Act (CanG); only the responsible authority remains to be appointed.

Research in all its forms is key to advancing both medical and societal progress in cannabis. This diversity in research underscores the value of scientific insights for destigmatization, therapeutic application, and social acceptance. Through ongoing studies, cannabis’s potential can be optimally utilized, paving the way for evidence-based regulations.

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

With legalising greetings,

US-Regulation today

Currently, cannabis remains illegal under federal law as a Schedule I drug, but state-level policies vary. Twenty-four states and D.C.—covering 53% of the population—have legalized cannabis for recreational use, while 38 states permit medical use. This disparity creates a complex legal landscape, often leading to excessive tax burdens and limited access to banking services for cannabis retailers. However, the upcoming election may change policies beyond US borders.

What’s on the Line for Cannabis Regulation?

For the first time, both major presidential candidates have shown support for a significant change in federal cannabis policy. This bipartisan shift suggests that regardless of who wins, the US may be inching toward a more unified approach to cannabis regulation. Voters in Florida, North Dakota, South Dakota, and Nebraska will also have a direct say in cannabis legalization through ballot measures, signaling the growing momentum for reform across the country.

Kamala Harris’s Position

Kamala Harris has been a prominent advocate for cannabis reform. In 2019, as a senator, she was the lead sponsor of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, a bill aimed at descheduling cannabis that would remove cannabis entirely from the Controlled Substances Act (CSA). Although it did not pass the Senate, this showcases how Harris’s stance on cannabis has evolved significantly over time. In 2010, as California’s Attorney General, she opposed a state measure to legalize recreational cannabis. And ten years later, she was advocating for complete federal legalization. Currently, as Vice President, Harris leads discussions on criminal justice and cannabis reform within the Biden administration, focusing on rescheduling cannabis under a less strict section of the CSA.

Donald Trump’s Position

Donald Trump’s position on cannabis has been more inconsistent. He supports the idea that the legalization of recreational cannabis should be left up to individual states and recently stated he would vote for Florida’s ballot measure to legalize it. Trump has also endorsed the rescheduling of cannabis under the CSA, aligning this aspect of his stance with the Biden administration’s current efforts. However, Trump’s approach to medicinal cannabis has been somewhat ambiguous. While he stated in 2016 that he “likes” cannabis when used for medicinal purposes and believes its health benefits should be explored further, he has also expressed doubts about its effectiveness, claiming it might do “significant damage.” Moreover, during his presidency, his administration took several anti-cannabis actions, including rescinding an Obama-era policy that directed federal officials not to pursue cannabis-related prosecutions in states where the drug is legal.

Rescheduling Uncertainty: Potential Ripple Effects on European Cannabis Policies

Rescheduling cannabis would be a significant reform but not equivalent to full descheduling. President Biden has acknowledged that rescheduling at the federal level is “not a done deal.” While the Justice Department proposed moving cannabis to Schedule III, the final decision lies with the DEA, with a public hearing scheduled for December 2. This uncertainty has weakened investor confidence. If rescheduling stalls, barriers to medical research and commercial activities will persist. Federal reclassification could also influence European policies, prompting countries to reconsider regulations and impacting trade, research, and legal frameworks, given the US’s role in the global cannabis market.

This election could mark a turning point for cannabis regulation, not just in the US but across the globe, as countries closely watch how the evolving American stance might shape the future of cannabis policy worldwide.

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

With legalising greetings,